Abstract
Multiple Myeloma (MM) remains an incurable plasma cell malignancy in the bone marrow (BM) despite conventional therapies as well as high-dose therapies with stem cell support. Therefore novel biologically-based therapeutic approaches are required. Recently, intensive laboratory and preclinical studies have identified and validated therapeutic molecular targets in MM. In particular, recognition of the biologic significance of the BM microenvironment in MM pathogenesis and as a potential target for novel therapeutics has derived several promising approaches. Novel FDA approved agents including thalidomide/thalomid®, its immunomodulatory derivatives lenalidomide/Revlimid®, and proteasome inhibitor bortezomib/Velcade® are directed at molecular targets not only in MM cells but also in its BM milieu, and have already achieved promising results in clinical studies. Here we discuss the mechanisms of action of these novel drugs and their clinical application, alone or combined with conventional or novel drugs.
Keywords: bone marrow stromal cells, VEGF, IL-6, Cytokines, fibroblast growth factor (bFGF), Cancer Therapy, proteasome inhibitor
Current Pharmaceutical Biotechnology
Title: Recent Advances in the Treatment of Multiple Myeloma
Volume: 7 Issue: 5
Author(s): Hiroshi Yasui, Teru Hideshima, Paul G. Richardson and Kenneth C. Anderson
Affiliation:
Keywords: bone marrow stromal cells, VEGF, IL-6, Cytokines, fibroblast growth factor (bFGF), Cancer Therapy, proteasome inhibitor
Abstract: Multiple Myeloma (MM) remains an incurable plasma cell malignancy in the bone marrow (BM) despite conventional therapies as well as high-dose therapies with stem cell support. Therefore novel biologically-based therapeutic approaches are required. Recently, intensive laboratory and preclinical studies have identified and validated therapeutic molecular targets in MM. In particular, recognition of the biologic significance of the BM microenvironment in MM pathogenesis and as a potential target for novel therapeutics has derived several promising approaches. Novel FDA approved agents including thalidomide/thalomid®, its immunomodulatory derivatives lenalidomide/Revlimid®, and proteasome inhibitor bortezomib/Velcade® are directed at molecular targets not only in MM cells but also in its BM milieu, and have already achieved promising results in clinical studies. Here we discuss the mechanisms of action of these novel drugs and their clinical application, alone or combined with conventional or novel drugs.
Export Options
About this article
Cite this article as:
Yasui Hiroshi, Hideshima Teru, Richardson G. Paul and Anderson C. Kenneth, Recent Advances in the Treatment of Multiple Myeloma, Current Pharmaceutical Biotechnology 2006; 7 (5) . https://dx.doi.org/10.2174/138920106778521569
DOI https://dx.doi.org/10.2174/138920106778521569 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Enzymatic Properties and Physiological Roles of Cytosolic 5’-Nucleotidase II.
Current Medicinal Chemistry Developing Target Therapy Against Oncogenic Tyrosine Kinase in Myeloid Maliganacies
Current Pharmaceutical Biotechnology Sumoylation Pathway as Potential Therapeutic Targets in Cancer
Current Molecular Medicine Radioimmunotherapy of Infection with 213Bi-Labeled Antibodies
Current Radiopharmaceuticals Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy
Current Medicinal Chemistry Novel Epigenetic Targets in Lymphoproliferative Disorders
Current Cancer Drug Targets Mixed Connective Tissue Disease (MCTD) – A Coming of Age
Current Rheumatology Reviews Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Current Drug Targets Optimizing Tumor-Reactive γδT Cells for Antibody-Based Cancer Immunotherapy
Current Molecular Medicine Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways
Current Cancer Drug Targets Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry Oncogenic MicroRNAs in the Genesis of Leukemia and Lymphoma
Current Pharmaceutical Design Polymers Based on Phenyl Boric Acid in Tumor-Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation
Current Drug Targets Interferon-Alpha in the Treatment of Multiple Myeloma
Current Drug Targets Targeted Therapies in Breast Cancer: Established Drugs and Recent Developments
Current Clinical Pharmacology Pharmacotherapy of Schizophrenia: The Past, Present and Future
Current Drug Therapy Retracted: miR-27b-3p Inhibits Invasion, Migration and Epithelial-mesenchymal Transition in Gastric Cancer by Targeting RUNX1 and Activation of the Hippo Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Gene Selection from Microarray Data Using Binary Grey Wolf Algorithm for Classifying Acute Leukemia
Current Signal Transduction Therapy Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry